Advanced Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 14, 2025
Abstract
High‐intensity
focused
ultrasound
(HIFU)
is
emerging
as
a
promising
non‐invasive
treatment
for
solid
tumors.
Nevertheless,
HIFU
may
also
induce
the
upregulation
of
Heat
Shock
Protein
90
(HSP‐90),
potentially
resulting
in
resistance
to
HIFU.
Besides,
although
it
effective
against
situ
tumors,
challenges
remain
with
tumor
metastasis
and
recurrence.
Herein,
innovative
design
gambogic
acid
(GA)
based
coordination
polymer—GAZn‐PEG
nanoparticles
(GAZn‐PEG
NPs)
are
synthesized
through
GA
zinc
ions
(Zn
2+
),
subsequently
functionalized
lipid
bilayer
incorporating
polyethylene
glycol
(PEG),
sensitizing
cervical
ovarian
cancers.
Briefly,
under
exposure,
markedly
suppresses
expression
HSP‐90,
thereby
increasing
tumor's
sensitivity
therapy.
Furthermore,
Zn
not
only
overcome
issue
GA's
poor
water
solubility
but
synergistically
stimulate
immune
responses
conjunction
GA.
More
intriguingly,
has
been
discovered
that
GAZn‐PEG
can
effectively
activate
cyclic
GMP‐AMP
synthase‐stimulator
interferon
genes
(cGAS‐STING)
pathway,
enhancing
provoked
by
Specifically,
NPs
show
remarkable
increase
dendritic
cell
activation
stimulation
cGAS‐STING
crucial
long‐term
protection
recurrence
metastasis.
Annals of Laboratory Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 8, 2025
Joo
Dong
Park,
M.S.,
Ha
Eun
Shin,
Ph.D.,
Yeon
Su
An,
B.S.,
Hye
Jung
Jang,
Juwon
Se-Na
Kim,
Chun
Gwon
and
Wooram
Ph.D..
Ann
Lab
Med
-0001;0:.
https://doi.org/10.3343/alm.2024.0380
Experimental Hematology and Oncology,
Journal Year:
2024,
Volume and Issue:
13(1)
Published: Aug. 5, 2024
Abstract
Chimeric
antigen
receptor
macrophage
(CAR-MΦ)
represents
a
significant
advancement
in
immunotherapy,
especially
for
treating
solid
tumors
where
traditional
CAR-T
therapies
face
limitations.
CAR-MΦ
offers
promising
approach
to
target
and
eradicate
tumor
cells
by
utilizing
macrophages’
phagocytic
antigen-presenting
abilities.
However,
challenges
such
as
the
complex
microenvironment
(TME),
variability
expression,
immune
suppression
limit
their
efficacy.
This
review
addresses
these
issues,
exploring
mechanisms
of
action,
optimal
construct
designs,
interactions
within
TME.
It
also
delves
into
ex
vivo
manufacturing
CAR-MΦ,
discussing
autologous
allogeneic
sources
importance
stringent
quality
control.
The
potential
synergies
integrating
with
existing
cancer
like
checkpoint
inhibitors
conventional
chemotherapeutics
are
examined
highlight
possible
enhanced
treatment
outcomes.
Furthermore,
regulatory
pathways
scrutinized
alongside
established
protocols
cells,
identifying
unique
considerations
essential
clinical
trials
market
approval.
Proposed
safety
monitoring
frameworks
aim
manage
adverse
events,
cytokine
release
syndrome,
crucial
patient
safety.
Consolidating
current
research
insights,
this
seeks
refine
therapeutic
applications,
overcome
barriers,
suggest
future
directions
transition
from
experimental
platforms
standard
care
options.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: April 11, 2024
Chimeric
antigen
receptor
(CAR)
T
cell
therapy
has
transformed
cancer
immunotherapy.
However,
significant
challenges
limit
its
application
beyond
B
cell-driven
malignancies,
including
limited
clinical
efficacy,
high
toxicity,
and
complex
autologous
product
manufacturing.
Despite
efforts
to
improve
CAR
outcomes,
there
is
a
growing
interest
in
utilizing
alternative
immune
cells
develop
cells.
These
offer
several
advantages,
such
as
major
histocompatibility
(MHC)-independent
function,
tumor
microenvironment
(TME)
modulation,
increased
tissue
infiltration
capabilities.
Currently,
products
from
various
subtypes,
innate
cells,
hematopoietic
progenitor
even
exosomes
are
being
explored.
often
show
enhanced
antitumor
diminished
superior
penetration.
With
these
benefits
mind,
numerous
trials
underway
access
the
potential
of
innovative
This
review
aims
thoroughly
examine
challenges,
existing
insights
on
new
treatment.
Advances in medical diagnosis, treatment, and care (AMDTC) book series,
Journal Year:
2024,
Volume and Issue:
unknown, P. 391 - 418
Published: Aug. 28, 2024
Cancer
immunotherapy
has
emerged
as
a
revolutionary
approach
in
the
fight
against
cancer.
Unlike
traditional
treatments
like
chemotherapy
and
radiation,
harnesses
power
of
body's
own
immune
system
to
identify
destroy
cancer
cells.
promising
therapy,
but
limitations
specificity
control
hinder
its
full
potential.
Synthetic
gene
circuits
offer
address
these
challenges.
This
chapter
emphasizes
diverse
applications
synthetic
immunotherapy.
Additionally,
authors
discuss
advantages
AND
gate
for
minimizing
off-target
effects,
engineered
bacteria
targeted
tumour
manipulation,
T-cell
engineering
enhanced
anti-tumour
activity.
Ultimately,
therapies
are
not
mutually
exclusive.
While
proven
effectiveness
accessibility,
hold
immense
promise
personalized,
long-term
solutions.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: Jan. 22, 2025
Molecular
imaging
technologies
have
significantly
transformed
cancer
research
and
clinical
practice,
offering
valuable
tools
for
visualizing
understanding
the
complex
tumor
immune
microenvironment.
These
allow
non-invasive
examination
of
key
components
within
microenvironment,
including
cells,
cytokines,
stromal
providing
crucial
insights
into
biology
treatment
responses.
This
paper
reviews
latest
advancements
in
molecular
imaging,
with
a
focus
on
its
applications
assessing
interactions
Additionally,
challenges
faced
by
are
discussed,
such
as
need
highly
sensitive
specific
agents,
issues
data
integration,
difficulties
translation.
The
future
outlook
emphasizes
potential
to
enhance
personalized
through
integration
artificial
intelligence
development
novel
probes.
Addressing
these
is
essential
fully
realizing
improving
diagnosis,
treatment,
patient
outcomes.
